Thrombocythemia, Essential: Clinical Trials

68 trials for Thrombocythemia, Essential, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

43 completed, 9 recruiting, 6 terminated, 5 active not recruiting. 68 Phase 1, 23 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 168Completed 43, Recruiting 9, Terminated 6, Active not recruiting 5, Withdrawn 3, Unknown 2
Phase 223Completed 16, Recruiting 2, Withdrawn 2, Active not recruiting 1, Terminated 1, Unknown 1

Follow Thrombocythemia, Essential: new trials by email Literature Review of Thrombocythemia, Essential trials Research Report on Thrombocythemia, Essential

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs)
Phase 1RecruitingDamora Therapeutics2502026-09-012026-10-27
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2182026-05-112026-11-13
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
ZE74-0282-0001 or placebo - Healthy Volunteers
Phase 1RecruitingEilean Therapeutics AU Pty Ltd642026-04-162026-07-28
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
INCA035784 - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation1202025-10-012026-08-06
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis
JBI-802 - Essential Thrombocythemia (ET), Polycythemia Vera
Phase 1 / Phase 2RecruitingJubilant Therapeutics Inc.702024-10-212026-11-17
A Study of GLB-001 in Patients With Myeloid Malignancies
GLB-001 - Polycythemia Vera, Essential Thrombocythemia
Phase 1RecruitingHangzhou GluBio Pharmaceutical Co., Ltd.1082024-05-242025-08-19
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1RecruitingFox Chase Cancer Center242024-04-052024-05-03
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
INCA033989, Ruxolitinib - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2902023-12-042026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
INCA033989, Ruxolitinib - Myeloproliferative Neoplasms
Phase 1Active not recruitingIncyte Corporation1602023-09-252026-08-10
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia
Phase 1Active not recruitingMarina Kremyanskaya72023-04-042026-09-28
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
N-Acetylcysteine - Myeloproliferative Neoplasm, MPN
Phase 1 / Phase 2RecruitingUniversity of California, Irvine272022-01-032026-03-10
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome
Phase 1Active not recruitingIncyte Corporation1402021-02-232026-04-01
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Phase 1TerminatedAstex Pharmaceuticals, Inc.202020-12-212024-08-02
Study of Select Combinations in Adults With Myelofibrosis
MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis
Phase 1WithdrawnNovartis Pharmaceuticals2020-11-302021-03-04
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Navitoclax, Ruxolitinib, Celecoxib - Myeloproliferative Neoplasm
Phase 1Active not recruitingAbbVie852019-11-082025-02-14
Dual Vaccine Trial in Myeloproliferative Neoplasms
PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia
Phase 1 / Phase 2CompletedInge Marie Svane92019-07-102023-07-13
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center402019-02-272026-07-16
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis
Phase 1 / Phase 2TerminatedOhio State University Comprehensive Cancer Center122019-02-202026-04-24
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
CALRLong36 peptide - Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia
Phase 1CompletedInge Marie Svane102018-06-202023-07-13
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
RG7388, Pegasys - Polycythemia Vera, Essential Thrombocythemia
Phase 1CompletedJohn Mascarenhas132015-04-012019-09-12

Showing 20 of 68. Sign in to see all of them.

Narrower conditions

Primary Myelofibrosis (61)  ·  Polycythemia Vera (56)  ·  Myeloproliferative Disorders (54)  ·  Leukemia, Myeloid, Acute (39)  ·  Leukemia, Myelomonocytic, Chronic (34)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (33)  ·  Myelodysplastic Syndromes (32)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (29)  ·  Leukemia (28)  ·  Burkitt Lymphoma (26)  ·  Lymphoma, Follicular (26)  ·  Lymphoma, Mantle-Cell (26)  ·  Lymphoma, B-Cell, Marginal Zone (25)  ·  Lymphoma, Large B-Cell, Diffuse (25)

Broader conditions

Hemic and Lymphatic Diseases (68)  ·  Blood Coagulation Disorders (67)  ·  Blood Platelet Disorders (67)  ·  Hemorrhagic Disorders (67)  ·  Bone Marrow Diseases (65)  ·  Hematologic Diseases (65)  ·  Thrombocytosis (65)  ·  Neoplasms (57)  ·  Neoplasms by Site (57)  ·  Bone Marrow Neoplasms (56)  ·  Hematologic Neoplasms (55)  ·  Disease Attributes (43)  ·  Leukemia, Myeloid (43)  ·  Neoplasms by Histologic Type (43)  ·  Pathologic Processes (43)

Interventions

Peripheral Blood Stem Cell Transplantation (9)  ·  ruxolitinib (9)  ·  Cyclophosphamide (6)  ·  Cyclosporine (6)  ·  fludarabine phosphate (5)  ·  Antilymphocyte Serum (4)  ·  Busulfan (4)  ·  Decitabine (4)  ·  Filgrastim (4)  ·  Methotrexate (4)  ·  Carboplatin (3)  ·  Cytarabine (3)  ·  Etoposide (3)  ·  Methylprednisolone (3)  ·  Tacrolimus (3)

Sponsors

National Cancer Institute (NCI) (7)  ·  Incyte Corporation (5)  ·  Fred Hutchinson Cancer Center (4)  ·  Eli Lilly and Company (3)  ·  California Cancer Consortium (2)  ·  Inge Marie Svane (2)  ·  M.D. Anderson Cancer Center (2)  ·  Mayo Clinic (2)  ·  Northwestern University (2)  ·  Novartis Pharmaceuticals (2)  ·  AbbVie (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Asan Medical Center (1)  ·  Astex Pharmaceuticals, Inc. (1)  ·  BioCryst Pharmaceuticals (1)

Countries

United States (56)  ·  Australia (8)  ·  Italy (8)  ·  Germany (7)  ·  United Kingdom (7)  ·  Canada (6)  ·  France (6)  ·  Belgium (5)  ·  Spain (5)  ·  Denmark (4)  ·  Japan (4)  ·  China (2)  ·  Netherlands (2)  ·  Poland (2)  ·  South Korea (2)

Top investigators

Jacob H Grauslund, MD (2)  ·  Jorge Cortes, MD (2)  ·  Richard K. Burt, MD (2)  ·  Ronald Hoffman, MD (2)  ·  Todd M. Zimmerman, MD (2)  ·  Alex Shalaurov, MD, PhD (1)  ·  Andrew Roberts, M.D. (1)  ·  Angela Fleischman, MD, PhD (1)  ·  Ann E. Woolfrey, MD (1)  ·  Ann Mohrbacher, MD (1)  ·  Aref Al-Kali (1)

Results publications

PMID 15570084, PMID 22259028, PMID 24474568, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 28934680, PMID 30562587, PMID 31167802, PMID 32634234, PMID 33718228, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 38259250

NIH funding

2018 (2), P30CA015083 (2), U01CA062491 (2), 2019 (1), 2023 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016058 (1), P30CA016086 (1), P30CA016087 (1), P30CA023074 (1), P30CA033572 (1), P30CA036727 (1), P30CA072720 (1)